Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH

News from the EULAR 2020 E-Congress

News from the EULAR 2020 E-Congress

03-06-2020 | EULAR 2020 | Conference coverage | News

Better disease CONTROL with add-on adalimumab vs methotrexate escalation in PsA

04-06-2020 | EULAR 2020 | Conference coverage | News

ARCTIC REWIND supports TNF inhibitor continuation in sustained RA remission

04-06-2020 | EULAR 2020 | Conference coverage | News

Structural entheseal lesions may predict PsA progression risk in patients with psoriasis

04-06-2020 | EULAR 2020 | Conference coverage | News

Sustained response to secukinumab for PsA patients with axial manifestations

04-06-2020 | EULAR 2020 | Conference coverage | News

​​​​​​​TNF inhibitors linked to reduced VTE risk in RA patients

04-06-2020 | EULAR 2020 | Conference coverage | News

VTE risk linked to high disease activity in RA

05-06-2020 | EULAR 2020 | Conference coverage | News

RE-EMBARK study sheds light on etanercept tapering in patients with nonradiographic axSpA

05-06-2020 | EULAR 2020 | Conference coverage | News

Phase 3 results ADVOCATE C5a receptor inhibition for ANCA-associated vasculitis

05-06-2020 | EULAR 2020 | Conference coverage | News

Belimumab shows promise for lupus nephritis

05-06-2020 | EULAR 2020 | Conference coverage | News

Upadacitinib shows promise for PsA

05-06-2020 | EULAR 2020 | Conference coverage | News

Adding csDMARD improves TNF inhibitor retention in axSPA

05-06-2020 | EULAR 2020 | Conference coverage | News

JAKPOT study takes a real-world look at JAK inhibitor retention vs TNF inhibitor

06-06-2020 | EULAR 2020 | Conference coverage | News

Etanercept linked to elevated risk for anterior uveitis in patients with SpA

06-06-2020 | EULAR 2020 | Conference coverage | News

No benefit of hydroxychloroquine for inflammatory, erosive hand osteoarthritis

06-06-2020 | EULAR 2020 | Conference coverage | News

Anakinra ‘an additional option’ to treat flares in difficult-to-treat gout

06-06-2020 | EULAR 2020 | Conference coverage | News

COVID-19 hospitalization: What do the data tell us?

07-06-2020 | EULAR 2020 | Conference coverage | News

EULAR issues provisional COVID-19 recommendations

08-06-2020 | EULAR 2020 | Conference coverage | News

Upadacitinib outperforms abatacept in head-to-head RA trial

08-06-2020 | EULAR 2020 | Conference coverage | News

No benefit of therapeutic drug monitoring in patients starting infliximab therapy

08-06-2020 | EULAR 2020 | Conference coverage | News

Sustained benefits with secukinumab in nonradiographic axial spondyloarthritis
Next